[Home]   [Full version]  

Novel model of osteosarcoma

Jun 15 ,Medicine & Health


In the June 15th issue of G&D, Dr. Stuart Orkin (HHMI, Dana-Farber Cancer Institute, Children's Hospital Boston) and colleagues present a new mouse model of osteosarcoma.

Osteosarcoma is the most common type of malignant bone cancer, and one of the most lethal: The 5-year survival rate is only about 60%, and this statistic drops steeply once the cancer spreads. Osteosarcoma results from the dysregulated growth of osteoblasts (the cells that form the bone matrix). It primarily develops near the ends of the femur, tibia or humerus, and is usually diagnosed during adolescence, when the long bones of the body are undergoing rapid growth.

While the precise causes of osteosarcoma are unknown, it is evident that two tumor suppressor genes – p53 and Rb – are involved, as children with familial mutation syndromes affecting either of these genes have higher incidences of osteosarcoma.

Dr. Orkin's team has developed a novel experimental system to model the genetics of human osteosarcoma. The researchers generated a strain of transgenic mice lacking specifically the p53 and Rb genes in an early osteoblast progenitor cell population. All mutant animals rapidly developed osteosarcomas, with clinical, histo-cytological and molecular features closely recapitulating the human disease.

The scientists concluded that p53 loss is essential for the development of osteosarcoma, and that while Rb gene mutation acts synergistically with p53 loss to facilitate carcinogenesis, loss of Rb, alone, is not sufficient to induce osteosarcomagenesis.

Ultimately, this high-fidelity animal model will further elucidate the genetic contributions to osteosarcoma, and enable researchers to rationally design and test new therapies. Dr. Orkin is hopeful that "our work will stimulate translational efforts to develop novel therapies for this devastating bone tumor".

Source: Cold Spring Harbor Laboratory

Related stories:

Study shows drug effective in treating, preventing breast cancer
A new study of an estrogen-derived drug shows promise as a treatment for breast cancer and breast cancer metastases to bone.
Cancer cures could work for canines and humans
One of the major issues associated with longer life expectancy in man and his best friend is an increase in the incidence of cancer. Even though they cannot talk it seems dogs might be able to tell us why and how certain cancers develop. In turn that could lead to better treatments for both canine and human cancer patients.
Nuclear reactor as a cancer cure
Despite the millions of dollars that have been invested into research to improve methods of treatments for various types of cancer, oncological diseases continue to have a high mortality rate, remaining one of the main causes of death globally. Traditional cancer treatment methods, such as chemotherapy, immunotherapy, and radiotherapy are effective in approximately only half of all patients.
A promising technology to more effectively treat certain cancers is Neutron Capture Therapy (NCT), a cutting-edge treatment method that uses neutrons captured during operation of a nuclear reactor to irradiate the tumor. A main advantage of NCT is the selective damage of tumor cells, avoiding many of the common severe side effects of other cancer treatment methods.

News discussion:

Medicine & Health news

[Home]   [Full version]